一种含有黄素的单氧化酶的结构指导工程,用于高效地生产间接
Bing-Yao Sun1, Hua-Lu Sui1, Zi-Wei Liu1
1State Key Lab of Bioreactor Engineering, Newworld Institute of Biotechnology, East China University of Science and Technology, Shanghai, 200237, China.
Bioresources and bioprocessing
|April 22, 2024
概括
研究人员通过对大肠杆菌中含有黄素的单氧化酶 (bFMO) 酶进行工程改造,增强了白血病治疗的印第鲁宾的产生. 这种以结构为导向的方法显著提高了酶活性和间接的产量.
科学领域:
- 生物化学 生物化学
- 酶工程是什么? 酶工程是什么?
- 代谢工程是代谢工程.
背景情况:
- 印都鲁是一种双醇化合物,研究用于治疗慢性髓细胞白血病.
- 对其治疗应用而言,高效的印鲁生产至关重要.
- 含有黄素的单氧化酶 (FMOs) 是可以用于生物催化工程的酶.
研究的目的:
- 开发一种以结构为导向的方法,以改善含有黄素的单氧化酶 (bFMO) 活性,以高效地生产间接.
- 确定 bFMO 中的关键结构区域,这些区域可用于增强催化功能的修改.
- 为了设计一种大肠杆菌菌株,用于高产率的无鲁生物合成.
主要方法:
- 对bFMO进行结构导向分析,以确定影响活动的可重新配置区域.
- bFMO的位点定向突变发生,重点是灵活的循环和基质道.
- 构建一个工程化的大肠杆菌菌株,结合代谢工程策略.
主要成果:
- 确定灵活的循环和基板道作为bFMO活动增强的关键地点.
- 突变K223R和N291T的催化活性分别增加了2.5倍和2.0倍.
- 一种组合突变 (K223R/D317S) 通过稳定 π-π 堆叠相互作用,使催化效率 (kcat/Km) 提高了 6.6 倍.
- 一种经过工程改造的大肠杆菌菌株实现了860.7 mg/L (18 mg/L/h) 的印第鲁宾的创纪录产量.
结论:
- 在FMO的结构导向工程可以显著提高酶活性.
- 在bFMO的特定修改,特别是针对灵活的循环和基板道,提高催化效率.
- 开发的代谢工程方法为高产率的印鲁生产提供了一个高效的平台,为治疗性化合物生物合成提供了一个有前途的战略.
相关概念视频
Induced-fit Model
77.0K
Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
77.0K
Bioreactor Controls-III
67
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
67
Production of Pharmaceuticals
94
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
94


